US Patent

US8470842 — Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor

Method of Use · Assigned to Opko Health Inc · Expires 2029-01-18 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects hydrochloride and tosylate crystalline salt forms of a specific compound and methods for preparing them.

USPTO Abstract

Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.

Drugs covered by this patent

rolapitant-hydrochloride (ROLAPITANT HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1741`	—	rolapitant-hydrochloride
`U-1741`	—	rolapitant-hydrochloride

Patent Metadata

Patent number: US8470842
Jurisdiction: US
Classification: Method of Use
Expires: 2029-01-18
Drug substance claim: No
Drug product claim: No
Assignee: Opko Health Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.